True but a higher share price puts ACHN on better negotiating terms since they can tell a prospective partner that they would dilute at $4 instead of $2 to get money for further trials.
You don’t seriously believe this, do you?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”